Given that SL candidates NDUFB5 in the STAD screen; MDM2 and TUBA1B in the COAD/READ screen; and WRN in the COAD/READ and pan-cancer screens were identified as the most promising therapeutic targets (priority class A) for KMT2DLOF cancers, we sought to understand the relationship between KMT2D and these genes further. This evidence concerns the gene NDUFB5 and cancer.